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Changes in the SC 2006 List of Reportable 
Conditions
Libby C. Greene, MSN, APRN, BC
Director - Surveillance Section/Nurse Consultant
    
Addition of Yersiniosis to 2006 List of 
Reportable Conditions
Marcia L. Headrick, DVM, MPH
State Public Health Veterinarian
I    
As authorized by South Carolina Statute #44-20-10 and 
Regulation #61-20, the S.C. Department of Health and 
Environmental Control (DHEC) updates the list of Reportable 
Conditions in January of each year.  Revisions to the list of 
reportable conditions are based on many factors, including: 1) 
the need for DHEC to conduct surveillance on new conditions 
or to increase surveillance on certain existing conditions in 
order to protect the health of the public and 2) changes in 
reporting requirements from the Centers for Disease Control 
and Prevention (CDC).
The following revisions have been made to the 2006 List of 
Reportable Conditions:
Deletions from the list: 
•	 Vancomycin-resistant enterococcus 
(VRE)
•	 HTLV I and II
Additions to the list of conditions to report
Within 7 Days: 
•	 Yersiniosis (Lab only)
 Revisions:   
•	 “Encephalitis, arthropod-borne disease” 
l isted in the "Urgently Reportable" 
conditions list has changed to: “Arboviral 
Neuroinvasive Disease (acute infection, 
including acute flaccid paralysis, atypical 
Guillain-Barré Syndrome): Eastern Equine 
Encephalitis (EEE), Lacrosse (LAC), St. 
Louis (SLE), West Nile Virus (WNV)”
•	 HIV quantification/viral load in the list of 
conditions to report within 7 Days:  “all 
results” has been added
In addition to the above changes, “genotyping” has been 
added to the List of Reportable Conditions in footnote #7 
located on the S.C. List of Reportable Diseases poster and 
on the web site.  Also, due to reorganization of DHEC county 
Yersiniosis is caused by the gram-negative bacillus,Yersinia 
enterocolitica. The organism is most commonly found in 
pork products, but has also been found in contaminated 
raw milk, ice cream, tofu, and shellfish.  It has also been 
identified in ponds, lakes, and 
streams contaminated by animal 
feces.  Yersiniosis is a zoonotic 
disease, a disease that can be 
transmitted between animals and 
humans.  It is usually transmitted 
to humans via consumption of 
food contaminated with animal 
feces, particularly swine feces. 
Most cases of yersiniosis are 
not diagnosed, possibly due 
to mild symptoms or because 
the disease is not commonly 
suspected and laboratory testing 
is not routinely conducted. 
Unfortunately, small children 
and infants are most often 
affected and their symptoms 
can be severe, including bloody 
diarrhea, abdominal pain, and 
fever.  Yersiniosis in older 
children and adults may mimic 
appendicitis.   Joint pain has 
also been reported in infected 
adults.
   
In the U.S., human outbreaks 
of yersiniosis have been linked 
to the consumption of pork 
chitterlings (large intestines). 
The preparation of chitterlings, 
often called “chitlin’s,” includes 
cleaning of the large intestines 
with a small brush.  During the 
cleaning process, there is significant potential for contamination 
of the cleaning area and cross-contamination of other 
foodstuffs.  Cases of yersiniosis linked to consumption
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(CHaNgES IN THE SC 2006 lIST cont'd from Page 1)
public health departments, please note on the Web site and 
on the poster that the public health departments are now 
listed by Regions rather than by Districts and that several of 
the addresses and phone numbers have changed.
The above changes may be found:
	 In this edition of the Epi Notes
	 On the DHEC Web site at: http://www.scdhec.
gov/  health/disease/index.htm or
 http://www.scdhec.gov/health/disease/docs/  
reportable_conditions.pdf
	 On the 2006 DHEC Disease Reporting Card
 (color is yellow for 2006)
	 On the 2006 list of Reportable Conditions poster.
 Both the Disease Reporting Cards and the
 laminated posters (sizes 8 ½ by 11 and 12 x 24)
 are available from your health departments or
 from the DHEC Division of Acute Disease
 Epidemiology in Columbia.
Removal of Laboratory Reported HTLV-
I and HTLV-II Infections from the 
2006 South Carolina List of Reportable 
Conditions 
Daniel Drociuk
Director - Response/Enhanced Surveillance Section
Human T-lymphotropic viruses types I (HTLV-I) and II (HTLV-
II) were the first human retroviruses discovered.1,2  They are 
only distantly related to the human immunodeficiency viruses 
(HIV-1 and HIV-2), which belong to the lentivirus subfamily 
of retroviruses and cause the acquired immunodeficiency 
syndrome (AIDS). Infections with HTLV-I and HTLV-II are 
most easily detected serologically, with the presence of 
antibodies to HTLV-I or HTLV-II indicating a person is infected 
with the virus.  In industrialized countries HTLV-II is prevalent 
among drug abusers and is spread by contaminated needles 
and by heterosexual transmission.
Public health interventions associated with the reporting of 
HTLV-I or HTLV-II infection are limited.  HTLV-I has been 
associated with adult T-cell leukemia/lymphoma (ATL) and 
a chronic degenerative neurologic disease, and HTLV-I-
associated myelopathy/tropical spastic paraparesis (HAM/
TSP). HTLV-II infection has not been clearly associated 
with any diseases with the virus first being isolated from two 
patients with hairy cell leukemia.  No evidence of HTLV-II 
infection was found in 21 additional patients with hairy cell 
leukemia who were examined.3
To those ends, laboratory reporting in South Carolina of HTLV-
I and HTLV-II infections are no longer required and have been 
removed from the 2006 List of Reportable Conditions.  
However, since HTLV-II is known to be endemic among 
several Amerindian populations in North, Central and 
South America, the potential for follow-up and investigation 
of possible clusters exists4 with serological and clinical 
information associated with possible cases required from 
providers to assist with the public health investigation.
References:
1 Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna 
JD, Gallo RC. Detection and isolation of type C retrovirus 
particles from fresh and cultured lymphocytes of a patient 
with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 
1980; 77:7415-9.
2 Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, 
Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell 
leukemia virus (HTLV-II) associated with a T-cell variant of 
hairy cell leukemia. Science. 1982; 218:571-3.
3 Centers for Disease Control and Prevention and the 
U.S.P.H.S. Working Group.  Guidelines for Counseling 
Persons Infected with Human T-Lymphotropic Virus Type I 
(HTLV-I) and Type II (HTLV-II).  Annals of Internal Medicine. 
15 March 1993; 118:448-454.
4 Reported on October 7, 2005 by EINet of an HTLV-1 
cluster in an Nunavut community.  Accessed on November 
25, 2005 at: http://depts.washington.edu/einet
newsbrief63.html?article=923#923
(YErSINIoSIS cont'd from Page 1)
of chitterlings occur most often during the winter holiday 
season since this is a traditional holiday food, especially 
in rural areas of the Southeastern United States, including 
South Carolina.  
Yersiniosis has not been a required reportable disease in 
S.C. in previous years.  However, according to inpatient 
and outpatient ICD-9 diagnostic data from the S.C. Hospital 
Discharge Data Set, twelve cases of yersiniosis have been 
identified in S.C. since 2000.  Due to the potential public 
health impact of outbreaks, yersiniosis will be added to the 
S.C. List of Reportable Conditions in 2006 for laboratory 
reporting only.  This will facilitate recognition of cases and 
initiation of appropriate public health action such as education 
on safe food handling practices.  Hospital laboratories should 
consider routinely culturing stool specimens submitted during 
the winter holiday season on cefsulodin-irgasan-novobiocin 
(CIN) agar, a medium selective for Yersinia.  Positive results 
should be reported to DHEC within seven days.  Stool 
specimens from suspect cases may be submitted to the 
DHEC Public Health Laboratory, if local laboratory testing 
is not available.
Additional information on yersiniosis is available from the 
CDC at the following Internet address: http://www.cdc.gov/
ncidod/dbmd/diseaseinfo/yersinia_g.htm
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 Changes in Reporting Antibiotic Resistant 
Organisms 
Dixie F. Roberts, MPH, RN
Director, Division of Acute Disease Epidemiology
Antibiotic resistance continues to be a significant public 
health problem.  Surveillance for the various types of 
resistance is complex and requires significant public health 
and health care system resources.  DHEC is participating 
in CDC programs and activities to establish an effective 
surveillance system and to select the organisms for which 
surveillance data is needed for public health action. Future 
Epi Notes articles will describe proposals for improving 
antibiotic resistant surveillance, while coping with limited 
resources. 
 The DHEC 2006 List of Reportable Conditions no longer 
requires individual case reporting on the DHEC Disease 
Report Cards for Vancomycin resistant enterococcus (VRE). 
However, outbreaks of VRE in a health care facility are still 
reportable to DHEC, as is any outbreak or unusual disease 
or cluster of cases.  
Since 1994, DHEC has required reporting of individual cases 
of patients with VRE positive cultures. S.C. data (figures 
1-3) are consistent with national data showing an increase 
in VRE infection and colonization, and possibly improved 
reporting.  Colonization with VRE is long term and accounts 
for positive cultures in the absence of disease. The data was 
reviewed for duplicate reports and, over a two-year period 
of time, at six months intervals, approximately ten percent 
of the reports were duplicates.  
Individual case based reporting to public health is not the best 
way to monitor this nosocomial problem.  The most critical 
data for prevention and control of VRE is that collected, 
analyzed, interpreted, and disseminated by each health 
care facility (e.g. hospital, long term care, dialysis centers). 
This facility-based data will allow for timely implementation 
of prevention and control measures.  To appropriately 
implement infection control measures, an important aspect 
of facility- based surveillance is the patient assessment 
performed by health care workers to identify risk factors for 
VRE colonization and symptoms of infection.    
As recommended in the 1998 SC DHEC Guidelines for 
Prevention and Control of Antibiotic Resistant Organisms in 
Health Care Settings, each health care facility should conduct 
surveillance for VRE, identify outbreaks and implement 
control measures, and monitor antibiograms for the isolates 
from their facility. Active surveillance culture programs and 
strict attention to infection control precautions have been 
shown to reduce nosocomial VRE transmission.  
Currently DHEC is working with some hospital and reference 
labs to send electronic laboratory reports to DHEC. These 
labs participating in the electronic lab 
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reporting projects should continue to submit VRE data. 
However, it is no longer necessary to complete the disease 
report cards for VRE.  Over the next year or two, as more 
laboratories begin to send data electronically, lab reporting 
will be an important part of public health surveillance for 
antibiotic resistance. This will reduce the burden on hospital 
personnel to complete the written disease reports. 
Streptococcus pneumoniae, invasive disease (including 
resistance patterns), and the urgently reportable Vancomycin 
resistant Staphylococcus aureus should continue to be 
reported as individual cases from hospitals, laboratories, 
and physicians. 
Digitized by South Carolina State Library
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"Get the Point" Program
Margie Davis
Infectious and Radioactive Waste Section
Bureau of Land and Waste Management
The South Carolina Department of Health and Environmental 
Control would like to remind the health care community of 
the existence and benefits of the  “Get the Point” program. 
This program is designed to educate individuals in the 
community who need to discard used needles/contaminated 
sharps (ie, diabetics). 
The “Get The Point” program is an inexpensive way to safely 
dispose of home-generated needles and sharps.  Home-
generated sharps are discarded in a 2-liter soda bottle.  Once 
the bottle is two-thirds full, it is tightly capped, sealed and 
labeled with a DO NOT RECYCLE sticker and thrown away 
in household trash.  Studies indicate that the recommended 
two-liter soda bottle is able to withstand more stresses 
around the home and at the landfill.  We are promoting this 
program to district nurse offices, public health department 
clinics, program nurse managers, home health services, 
doctor’s offices and hospitals within the State.  
Brochures explaining the program and stickers to distribute 
in health care settings may be obtained by contacting 
Margie Davis at davisml@dhecsc.gov.  Below is a Web 
site for the program.  We will also be happy to visit areas 
with brochures and stickers and demonstrate this important 
community program.  
 
DHEC is also committed to assisting the community with 
questions involving accidental needle-sticks and the disposal 
of sharps.  Needle-stick inquiries are referred to DHEC 
health professionals and staff who can advise a person on 
the best course of action until the person is able to see their 
health care provider.
http://www.scdhec.net/lwm/html/infect.html
Neuroinvasive Disease - A New Term For 
Arboviral Encephalitides
Lena M. Bretous, MD, MPH
Medical Epidemiologist
The revised terminology concerning arboviral meningitis 
and encephalitis follows the new CDC terminology for 
more severe arboviral disease.  In recent years, the terms 
encephalitis, meningitis, or meningoencephalitis have been 
used interchangeably.  For better quality assurance of data 
collection and recording of clinical syndromes associated 
with West Nile virus disease, the term neuroinvasive has 
replaced terms such as encephalitis or meningitis.  The term 
neuroinvasive is used as part of the CDC case definition for 
all arboviral diseases formerly known as encephalitides. 
   Ask Epi
Post-exposure Prophylaxis after 
Pre-exposure Prophylaxis?
Eric Brenner, MD
Medical Epidemiologist
At the DHEC Bureau of Disease Control we regularly field 
questions from providers rconcerning infectious diseases, 
public health, and epidemiology. We invite our readers to 
submit questions to AskEpi@sc.dhec.gov.  In recent issues 
this column has discussed the problem of false positive IgM 
tests and issues relating to BCG vaccine efficacy and its 
impact on the interpretation of subsequent tuberculin skin 
tests. Here, we address a question relating to post-exposure 
prophylaxis of Hepatitis A (and other infectious diseases).
Question:  In our practice we recently saw a child from out-
of-state who had been a household contact to a recently 
diagnosed case of hepatitis A.  Since we had seen the child 
within14 days following her exposure to the source case, 
she seemed to be a candidate to receive Immune Globulin 
(IG) as post-exposure prophylaxis. However, the child’s 
vaccine record showed she had previously received hepatitis 
A vaccine.  The question, therefore, was whether IG was still 
indicated in this situation.
Ask Epi’s Answer:    Though this question relates to a 
particular situation involving hepatitis A,  it also provides 
a good opportunity to consider the more general question 
about when, whether, and why pre-exposure prophylaxis 
(PrEP) [usually a vaccine] may, or may not, modify otherwise 
standard indications for post-exposure prophylaxis (PoEP). 
We will address this more general question through several 
hypothetical case scenarios:
Scenario 1 -  Pertussis:  Two siblings, a20 month-old and 
a 2 month-old have been exposed to a case of pertussis.  
The 20-month-old has received four doses of DTP; the 
2-month old has yet to receive a single dose.  Standard 
guidelines1 recommend that the children's immunization 
histories not be taken into account and that both children 
receive identical courses of PoEP with erythromycin (or 
with a newer macrolide). 
Scenario 2 -  Rabies:  A  forestry field worker has previously 
received PrEP rabies vaccine because of potential 
occupational risk.  While walking in the woods,  he is bitten 
(Continued on Page 8)	
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by a raccoon. the racoon tests postive for rabies.   Although 
rabies PoEP normally calls for administration of Rabies 
Immune Globulin (RIG) and five doses of rabies vaccine 
administered over a 28-day period, recommendations for this 
previously vaccinated patient are that he need not receive 
RIG and needs to receive only two doses of rabies vaccine, 
administered over a 4-day period.2
Scenario 3 - Hepatitis A:  This scenario is the one that 
described in the question addressed to "Ask Epi" above. 
Here standard guidelines state that: “Persons who have been 
recently exposed to HAV and who have not previously been 
administered hepatitis A vaccine should be administered a 
single IM dose of IG (0.02 mL/kg) as soon as possible, but 
not >2 weeks after the last exposure. Persons who have been 
administered one dose of hepatitis A vaccine at least 1 month 
before exposure to HAV do not need IG".3
Comment:  These scenarios illustrate that the details and 
inter-relationships between PrEP and PoEP are complex and 
vary from one infectious disease to another. Thus, following 
PrEP and then an “exposure”, PoEP may:
(a) remain necessary without modification of guidelines 
(e.g. pertussis)
(b) remain necessary but with modified details (e.g. 
rabies)
(c) not be necessary and may be dispensed with 
altogether (hepatitis A)
Further, for some diseases, guidelines regarding PoEP are 
so complex, with the best course of action dependent on 
many variables,  that recommendations cannot readily be 
presented in a single sentence or two;  rather, they must be 
presented in a structured table.  
A familiar example is the table summarizing the approach to 
tetanus PoEP where the need to administer Tetanus Immune 
Globulin (TIG) and/or a booster dose of Td depends on: (a) 
the number of  doses of TT/Td/DPT previously received, (b) 
the number of years since the last dose was administered, 
and (c) the nature and extent of the wound.1
 Likewise, the approach to needle stick Hepatitis B PoEP is 
summarized in an even more complex table which takes into 
account the vaccination and antibody response status of the 
exposed person and what is known about the HBsAg status of 
the source.4  In the case of HIV the  issues surrounding PoEP 
following occupational exposures (e.g. needle sticks) are so 
complex that even in the absence of any recommendations 
for PrEP a dozen pages or more are required to present the 
latest recommendations.5
In a few instances specific guidance on the relationship 
between PoEP and PrEP are lacking.  For example, 
following the January 2005 licensure of the new tetravalent 
meningococcal polysaccharide-protein conjugate vaccine, 
the CDC published updated recommendations regarding the 
prevention and control of meningococcal disease.6
However, in the section devoted to Antimicrobial 
Chemoprophylaxis, no mention at all is made of whether 
or how standard recommendations for PoEP antibiotic 
chemoprophylaxis ought to be modified for persons who 
have received the vaccine.  Thus, pending future guidance, 
management of a teenager who had received the vaccine but 
was later found to be a close (e.g. household) contact to a 
case of meningococcal meningitis would have to depend on 
“expert opinion” rather than on published guidelines.  
This last example notwithstanding, current versions of 
standard guidelines (such as those from the US Centers 
for Disease Control or the American Academy of Pediatrics) 
include considerably more detailed guidance than was 
available in earlier versions. Thus, the majority of situations 
commonly encountered in clinical practice are now explicitly 
addressed. 
Local public health departments as well as DHEC’s Division 
of Acute Disease Epidemiology (Tel: 803-898-0861) 
are available for consultation regarding issues of post-
exposure prophylaxis for individuals or groups exposed to 
communicable diseases.
References:
1. American Academy of Pediatrics. Red Book - Report 
of the Committee on Infectious Diseases.  26th edition, 
2003.  (for pertussis: p. 475; for Tetanus: table 3.61, p. 
614).
2. CDC.  Human Rabies Prevention — United States, 
1999.  MMWR January 8, 1999 / Vol. 48 / No. RR-1.
3. CDC.  Prevention of Hepatitis A Through Active or 
Passive Immunization.   MMWR October 1, 1999 / Vol. 
48 / No. RR-12.
4. Updated U.S. Public Health Service Guidelines for 
the Management of Occupational Exposures to HBV, 
HCV, and HIV and Recommendations for Postexposure 
Prophylaxis.  MMWR June 29, 2001 / Vol. 50 / No. RR-
11.
5. CDC.  Update U.S. Public Health Service Guidelines 
for the Management of Occupational Exposures to HIV 
and Recommendations for Postexposure Prophylaxis. 
MMWR September 30, 2005 / Vol 54 / No. RR-9.
6. CDC.  Prevention and Control of Meningococcal 
Disease.  MMWR May 27, 2005 / Vol. 54 / No. RR-7.
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Year-to-Date Summary of Reportable Conditions*
September 28, 2005  -  December 2, 2005
Epi Notes                Page 9                              Winter 2006
* This report does not include reportable STD conditions.
Condition Confirmed Probable Total
Aseptic meningitis 75 24 99
Bacterial meningitis- other 2  2
Brucellosis 1  1
Campylobacteriosis 193 2 195
Cryptosporidiosis 21 1 22
Cyclosporiasis 3  3
Dengue Fever 1  1
Ehrlichiosis- human granulocytic 6 3 9
Ehrlichiosis- human monocytic 1 3 4
Ehrlichiosis- human- other&unspec  4 4
Encephalitis- Eastern equine 1  1
Encephalitis- West Nile 3  3
Enterohem. E.coli O157:H7 8  8
Enterohem.E.coli shigatox+- ?serogrp 2 1 3
Enterohem.E.coli- shigatox+- non-O157 1  1
Giardiasis 97 2 99
Group A Streptococcus- invasive 31  31
Group B Streptococcus- invasive 18  18
Haemophilus influenzae- invasive 31  31
Hemolytic uremic synd- postdiarrheal 1  1
Hepatitis A- acute 35 4 39
Hepatitis B- acute 126 24 150
Hepatitis B virus infection- chronic 522 80 602
Hepatitis C- acute 1 3 4
Hepatitis C Virus Infection- chronic or resolved 2184 2223 4407
HTLV-I infection 1  1
HTLV-II infection 2  2
Influenza- human isolates 51  51
Influenza- Rapid Test 2 1 3
Influenza-like Illness 1  1
Kawasaki disease 2 1 3
Legionellosis 14 2 16
Listeriosis 13  13
Lyme disease 15 7 22
Malaria 9  9
Mumps 1  1
Neisseria meningitidis- invasive (Mening. disease) 14 1 15
Pertussis 337 36 373
Q fever  1 1
Rocky Mountain spotted fever 21 55 76
S. aureus- coag+- meth- or oxi- resistant (MRSA) 3  3
Salmonellosis 1113 246 1359
Scombroid fish poisoning 2  2
Shigellosis 92 4 96
Strep pneumoniae- invasive 153 2 155
Streptococcal disease- invasive- other 20  20
Vancomycin-Resistant Enterococcus 1353 5 1358
Varicella (Chickenpox) 194 328 522
Vibrio spp.- non-toxigenic- other or unspecified 5  5
West Nile Fever 2  2
Yersiniosis 2  2
*
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F O R   D I S E A S E   R E P O R T I N G
For immediately reportable conditions, call your local 
county  health department or,  for after-hours, call 
1-888-847-0902. Routine reports may be phoned in to 
your local health department or mailed on a completed 
DHEC DISEASE REPORTING CARD (DHEC 1129) . 
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